Amphastar Pharmaceuticals (AMPH) vs Nanobiotix S.A. (NBTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Amphastar Pharmaceuticals (AMPH) has outperformed Nanobiotix S.A. (NBTX) over the past year, losing 0.7% versus a loss of 16.1%. Over five years, NBTX leads with a +78.6% price change compared with +35.1% for AMPH. Nanobiotix S.A. is the larger company by market cap ($1.17 billion vs $1.10 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMPH | NBTX |
|---|---|---|
| Share price | $25.81 | $22.90 |
| Market cap | $1.10B | $1.17B |
| 1-day change | +1.06% | -6.99% |
| YTD return | -3.62% | -0.95% |
| 1-year return | -0.65% | -16.12% |
| 5-year return | +35.06% | +78.63% |
| P/E ratio (TTM) | 15.27 | — |
| Forward P/E | 8.11 | — |
| EPS (TTM) | $1.69 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.52 | $57.14 |
| 52-week low | $16.65 | $14.78 |
| Distance from 52-week high | -12.57% | -59.92% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -12.82% | +135.28% |
| Average volume | 472.25K | 150.18K |
| Shares outstanding | 42.54M | 50.92M |
| Employees | 1,976 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMPH has outperformed NBTX by 15.5 percentage points over the past year.
About Amphastar Pharmaceuticals
AMPH stock →Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees
About Nanobiotix S.A.
NBTX stock →Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
AMPH vs NBTX FAQ
Which is bigger, Amphastar Pharmaceuticals or Nanobiotix S.A.?
Nanobiotix S.A. (NBTX) is larger, with a market capitalization of $1.17B compared with $1.10B for Amphastar Pharmaceuticals (AMPH).
Which stock has performed better over the past year, AMPH or NBTX?
AMPH returned -0.65% over the past 12 months, compared with -16.12% for NBTX (price return, excluding dividends). Past performance does not predict future results.
Are Amphastar Pharmaceuticals and Nanobiotix S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.